TrialDiabetes care2016

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.

Muhammad Abdul-Ghani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.